Award
NIH Reporter #5R01AI195133-02
Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (HISTO-FACT)
Recipient
University of Minnesota
Award Amount
$841,046.00
Ceiling
$841,046.00
Awarded
August 19, 2026
Identifier
5R01AI195133-02
NIH funded Phase III clinical trial led by University of Minnesota to evaluate and improve therapies for histoplasmosis in people with HIV, awarded $841,046 for fiscal year 2026.
Description
This is a Phase III clinical trial funded by the NIH to evaluate therapies for histoplasmosis in people with HIV. The trial compares high-dose liposomal amphotericin B to standard dosing, and posaconazole to itraconazole, with the goal of improving safety, efficacy, and reducing treatment duration. The project is led by the University of Minnesota, with a total award of approximately $841,046 for the fiscal year 2026. The project start date is September 3, 2025, and end date is August 31, 2032.